RxDoctor Payments Data

Juan Guzman-Negron, MD

Urogynecology and Reconstructive Pelvic Surgery · Bayamon, PRNPI 1013222959

Payments from drug & device makers

$18,589in general payments, 2019–2025

Across 90 payments — averaging $206.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Procept Biorobotics Corporation$2K
  • Teleflex LLC$764
  • Boston Scientific$540
  • Axonics, Inc.$424
  • Rochester Medical Corporation$423
  • plus $934 from 11 others

What the payments were for

  • Speaking & faculty fees$10,67557%
  • Travel & lodging$3,33918%
  • Food & beverage$4,42024%
  • Education$1551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)34$13,705
Procept Biorobotics Corporation5$1,798
Teleflex LLC8$764
Boston Scientific8$540
Axonics, Inc.4$424
Rochester Medical Corporation8$423
Astellas Pharma US Inc9$284
Olympus Latin America, Inc.2$160
Merck1$124
E.r. Squibb & Sons, L.L.C.1$100
C. R. Bard, Inc. & Subsidiaries2$79
Johnson & Johnson2$47
Tolmar, Inc.2$42
Coloplast1$30
Therapeuticsmd, Inc.1$26
AbbVie1$25
Olympus America Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$19,140
Medicare patients
43
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron441$212,567
Estradiol368$30,053
Darifenacin ErDarifenacin Hydrobromide254$28,634
PremarinEstrogens, Conjugated33$14,802
Trospium Chloride ErTrospium Chloride23$2,961
Oxybutynin Chloride ErOxybutynin Chloride133$2,148
Methenamine Hippurate25$1,490
Fosfomycin Tromethamine15$1,461
Tolterodine Tartrate ErTolterodine Tartrate31$1,288
Tamsulosin Hcl102$1,157
Alfuzosin Hcl ErAlfuzosin Hcl47$663
Trospium Chloride11$610
Cephalexin231$554
Ketorolac Tromethamine32$483
Finasteride23$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$284$212,567441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Bayamon

Where these figures come from

Is this you, or does something look wrong? →